目的:探讨超声引导下甲状腺细针穿刺活检(ultrasound-guided fine-needle aspiration biopsy,US-FNAB)细胞学检查联合BRAF^(V600E)基因检测在超声甲状腺影像报告和数据系统(thyroid imaging reporting and data system,TI-RADS)为4类、...目的:探讨超声引导下甲状腺细针穿刺活检(ultrasound-guided fine-needle aspiration biopsy,US-FNAB)细胞学检查联合BRAF^(V600E)基因检测在超声甲状腺影像报告和数据系统(thyroid imaging reporting and data system,TI-RADS)为4类、5类甲状腺结节中的诊断价值,以期更好地对甲状腺结节进行术前定性诊断。方法:回顾性分析2021年01月至2022年12月于我院行甲状腺超声引导下细针穿刺并行BRAF^(V600E)基因突变检测的2 252例甲状腺结节患者资料,以手术后病理结果为结节性质诊断的对照标准,观察细针穿刺细胞学检查联合BRAF^(V600E)基因检测在诊断甲状腺乳头状癌中的准确率。结果:通过细针穿刺细胞学联合BRAF^(V600E)基因突变检测发现,在TI-RADS 4A、4B、4C、5类结节中,乳头状癌的构成比分别为38.4%、77.1%、85.3%、92.8%,与术后病理结果基本一致。结论:TI-RADS4类和5类的甲状腺结节,进行US-FNAB联合BRAF^(V600E)基因检测可以更好的鉴别甲状腺结节的性质,对术前定性诊断有重要的临床意义。展开更多
BACKGROUND Patients with BRAF V600E mutant metastatic colorectal cancer(mCRC)have a low incidence rate,poor biological activity,suboptimal response to conventional treatments,and a poor prognosis.In the previous cohor...BACKGROUND Patients with BRAF V600E mutant metastatic colorectal cancer(mCRC)have a low incidence rate,poor biological activity,suboptimal response to conventional treatments,and a poor prognosis.In the previous cohort study on mCRC conducted by our team,it was observed that integrated Chinese and Western medicine treatment could significantly prolong the overall survival(OS)of patients with colorectal cancer.Therefore,we further explored the survival benefits in the population with BRAF V600E mutant mCRC.AIM To evaluate the efficacy of integrated Chinese and Western medicine in the treatment of BRAF V600E mutant metastatic colorectal cancer.METHODS A cohort study was conducted on patients with BRAF V600E mutant metastatic colorectal cancer admitted to Xiyuan Hospital of China Academy of Chinese Medical Sciences and Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region from January 2016 to December 2022.The patients were divided into two cohorts.RESULTS A total of 34 cases were included,with 23 in Chinese-Western medicine cohort(cohort A)and 11 in Western medicine cohort(cohort B).The median overall survival was 19.9 months in cohort A and 14.2 months in cohort B,with a statistically significant difference(P=0.038,hazard ratio=0.46).The 1-3-year survival rates were 95.65%(22/23),39.13%(9/23),and 26.09%(6/23)in cohort A,and 63.64%(7/11),18.18%(2/11),and 9.09%(1/11)in cohort B,respectively.Subgroup analysis showed statistically significant differences in median OS between the two cohorts in the right colon,liver metastasis,chemotherapy,and first-line treatment subgroups(P<0.05).CONCLUSION Integrated Chinese and Western medicine can prolong the survival and reduce the risk of death in patients with BRAF V600E mutant metastatic colorectal cancer,with more pronounced benefits observed in patients with right colon involvement,liver metastasis,combined chemotherapy,and first-line treatment.展开更多
目的探讨合肥不同民族甲状腺结节患者间BRAF^(V600E)与临床病理特征的关系,评估BRAF^(V600E)与甲状腺影像报告和数据系统(Thuroid imaging reporting and data system of US Features,TI-RADS)、Bethesda系统诊断良恶性的价值,筛选出更...目的探讨合肥不同民族甲状腺结节患者间BRAF^(V600E)与临床病理特征的关系,评估BRAF^(V600E)与甲状腺影像报告和数据系统(Thuroid imaging reporting and data system of US Features,TI-RADS)、Bethesda系统诊断良恶性的价值,筛选出更有利的检测方法。方法选取两家医院共353例甲状腺结节患者资料,根据民族类型分为汉族组(n=254)和少数民族组(n=99)。PCR检测两组患者BRAF^(V600E)基因突变情况;以术后病理诊断结果为金标准,分别比较BRAF^(V600E)基因突变与TI-RADS、Bethesda系统的诊断价值。结果合肥地区353例甲状腺结节患者中,BRAF^(V600E)基因突变率为82.7%。BRAF^(V600E)与Bethesda系统联合检测甲状腺良恶性的诊断效能最高。结论合肥地区甲状腺结节患者BRAF^(V600E)突变在汉族和少数民族之间存在一定差异,BRAF^(V600E)与Bethesda系统联合检测可提高当地甲状腺癌的诊断效能。展开更多
基金Supported by National Natural Science Foundation of China,No.82174461Hospital Capability Enhancement Project of Xiyuan Hospital,CACMS,No.XYZX0201-22Technology Innovation Project of China Academy of Chinese Medical Sciences,No.CI2021A01811.
文摘BACKGROUND Patients with BRAF V600E mutant metastatic colorectal cancer(mCRC)have a low incidence rate,poor biological activity,suboptimal response to conventional treatments,and a poor prognosis.In the previous cohort study on mCRC conducted by our team,it was observed that integrated Chinese and Western medicine treatment could significantly prolong the overall survival(OS)of patients with colorectal cancer.Therefore,we further explored the survival benefits in the population with BRAF V600E mutant mCRC.AIM To evaluate the efficacy of integrated Chinese and Western medicine in the treatment of BRAF V600E mutant metastatic colorectal cancer.METHODS A cohort study was conducted on patients with BRAF V600E mutant metastatic colorectal cancer admitted to Xiyuan Hospital of China Academy of Chinese Medical Sciences and Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region from January 2016 to December 2022.The patients were divided into two cohorts.RESULTS A total of 34 cases were included,with 23 in Chinese-Western medicine cohort(cohort A)and 11 in Western medicine cohort(cohort B).The median overall survival was 19.9 months in cohort A and 14.2 months in cohort B,with a statistically significant difference(P=0.038,hazard ratio=0.46).The 1-3-year survival rates were 95.65%(22/23),39.13%(9/23),and 26.09%(6/23)in cohort A,and 63.64%(7/11),18.18%(2/11),and 9.09%(1/11)in cohort B,respectively.Subgroup analysis showed statistically significant differences in median OS between the two cohorts in the right colon,liver metastasis,chemotherapy,and first-line treatment subgroups(P<0.05).CONCLUSION Integrated Chinese and Western medicine can prolong the survival and reduce the risk of death in patients with BRAF V600E mutant metastatic colorectal cancer,with more pronounced benefits observed in patients with right colon involvement,liver metastasis,combined chemotherapy,and first-line treatment.
文摘目的探讨合肥不同民族甲状腺结节患者间BRAF^(V600E)与临床病理特征的关系,评估BRAF^(V600E)与甲状腺影像报告和数据系统(Thuroid imaging reporting and data system of US Features,TI-RADS)、Bethesda系统诊断良恶性的价值,筛选出更有利的检测方法。方法选取两家医院共353例甲状腺结节患者资料,根据民族类型分为汉族组(n=254)和少数民族组(n=99)。PCR检测两组患者BRAF^(V600E)基因突变情况;以术后病理诊断结果为金标准,分别比较BRAF^(V600E)基因突变与TI-RADS、Bethesda系统的诊断价值。结果合肥地区353例甲状腺结节患者中,BRAF^(V600E)基因突变率为82.7%。BRAF^(V600E)与Bethesda系统联合检测甲状腺良恶性的诊断效能最高。结论合肥地区甲状腺结节患者BRAF^(V600E)突变在汉族和少数民族之间存在一定差异,BRAF^(V600E)与Bethesda系统联合检测可提高当地甲状腺癌的诊断效能。
